Affordable Access

Publisher Website

Inhibition in vitro de la croissance deChlamydia trachomatispar des cyclines encapsulées dans les liposomes

Pathologie Biologie
Publication Date
DOI: 10.1016/s0369-8114(00)00005-5
  • Chlamydia Trachomatis
  • Doxycycline
  • Liposomes
  • Tétracycline
  • Liposome
  • Tetracycline


Abstract The antichlamydial activity of tetracycline (Tet) and doxycycline (Dox) encapsulated in cationic (CaL), anionic (AnL) and neutral (NtL) liposomes has been evaluated in vitro by adding serial dilutions of antibiotics (minimum inhibitory concentration, MIC: 0.12–0.007 μg/ml; MBC: 4 to 0.25 μg/ml) to HeLa 229 cell monolayers inoculated with Chlamydia trachomatis L 2/434/Bu (10 3 ufi/ml). Following 72 h incubation at 37°C under a 5% CO 2 atmosphere, the chlamydial inclusions were stained by the May-Giemsa method to determine the MICs. After a second and third passage, the MBC 1 and MBC 2 were determined in antibiotic-free medium. The chlamydial inclusions were then counted to assess the degree of growth inhibition at each antibiotic dilution tested for MBC 1 and MBC 2 determinations. The MIC, MBC 1 and MBC 2 of the various antichlamydial agents were as follows: Tet (0.12; 4; 4), AnL-Tet (0.01; 1; 1), NtL-Tet (0.03; 1; 2), Dox (0.06; 1; 2), CaL-Dox (0.03; 0.5; 2), AnL-Dox (0.01; 1; 2), and NtL-Dox (0.03; 0.5; 0.5). It was found that Tet and Dox liposome-encapsulated antibiotics were more active than their non-encapsulated counterparts, and the inclusion count showed a higher inhibitory activity of the former antibiotics on chlamydial growth. The inhibition of chlamydial growth by AnL-Tet may be of bactericidal nature. In conclusion, liposome-encapsulated drugs could be of value in the treatment of chlamydial infections

There are no comments yet on this publication. Be the first to share your thoughts.